Gilead Sciences (GILD) Cash from Operations (2009 - 2026)
Gilead Sciences' (GILD) quarterly Cash from Operations came in at 2544000000.0 in Q1 2026, up 44.79% YoY from 1757000000.0 in Q1 2025, and down 23.53% on a QoQ basis from 3327000000.0 in Q4 2025.
Gilead Sciences (GILD) Cash from Operations (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Cash from Operations data on file, last reported at 2544000000.0 in Q1 2026.
- Quarterly Cash from Operations rose 44.79% year-over-year to 2544000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10806000000.0 (up 4.24% YoY) and the FY2025 annual result came in at 10019000000.0, down 7.47% from the prior year.
- Cash from Operations slipped to 2544000000.0 in Q1 2026, from 3327000000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 4309000000.0 in Q3 2024 to a low of 827000000.0 in Q2 2025.
- A 5-year average of 2380529411.76 and a median of 2219000000.0 in 2024 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 145.53% in 2024, down 43.33% in 2024.
- Tracing GILD's Cash from Operations over 5 years: stood at 2567000000.0 in 2022, then retreated by 15.5% to 2169000000.0 in 2023, then surged by 37.16% to 2975000000.0 in 2024, then advanced by 11.83% to 3327000000.0 in 2025, then slipped by 23.53% to 2544000000.0 in 2026.
- The last three Cash from Operations figures came in at 2544000000.0 (Q1 2026), 3327000000.0 (Q4 2025), and 4108000000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Bn |
| Jun 30, 2026 | 3.57 Bn |
| Mar 31, 2026 | 2.54 Bn |
| Mar 31, 2026 | 2.54 Bn |
| Dec 31, 2025 | 3.33 Bn |
| Dec 31, 2025 | 3.33 Bn |
| Sep 30, 2025 | 4.11 Bn |
| Sep 30, 2025 | 4.11 Bn |
| Jun 30, 2025 | 827.00 Mn |
| Jun 30, 2025 | 827.00 Mn |
| Mar 31, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 2.98 Bn |
| Dec 31, 2024 | 2.98 Bn |
| Sep 30, 2024 | 4.31 Bn |
| Sep 30, 2024 | 4.31 Bn |
| Jun 30, 2024 | 1.33 Bn |
| Jun 30, 2024 | 1.33 Bn |
| Mar 31, 2024 | 2.22 Bn |
| Mar 31, 2024 | 2.22 Bn |